Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...
Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and ...
Stocktwits on MSN
'Pharma Bro' Martin Shkreli defends Revolution Medicines' pancreatic cancer study data: 'Progress compounds'
Revolution said on Monday that its late-stage trial evaluating its experimental cancer drug daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma, who had been previously treated, ...
REDWOOD CITY, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...
REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, ...
April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly ...
REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results